Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients

Journal of Clinical Pharmacology

Volumn 37, Issue 7, 1997, Pages 575-586

  Gruber, Scott A ^a   Gallichio, Michael ^a   Rosano, Thomas G ^a   Kaplan, Sandra S ^a   Hughes, Stephen E ^a   Urbauer, Diana L ^a   Singh, T Paul ^a   Lempert, Neil ^a   Conti, David J ^a   Stein, Daniel S ^a   Drusano, George ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN G;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY;

EID: 0030761507     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04339.x     Document Type: Article

References (70)

1. McKenzie N, Devineni R, Vezina W, Keown P, Stiller C: The effect of cyclosporine on organ blood flow. Transplant Proc 1985; 17:1973-1975.
2. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2:477-479.
3. Carrier M, Tronc F, Stewart D, Pelletier LC: Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. Am J Physiol 1991; 261:H1791-H1796.
4. Perico N, Ruggenenti P, Gaspari F, Mosconi L, Benigni A, Amuchastegui CS, et al: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54:56-60.
5. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37:1487-1481.
6. Carrier M, Perrault LP, Tronc F, Stewart DJ, Pelletier CL: Pentoxifylline decreases cyclosporine-induced renal endothelin release and vasoconstriction. Ann Thorac Surg 1993; 55:490-492.
7. Benigni A, Perico N, Ladny JR, Imberti O, Bellizzi L, Remuzzi G: Increased urinary excretion of endothelin-1 and its precursor, big-endothelin-1, in rats chronically treated with cyclosporine. Transplantation 1991; 52:175-177.
8. Brooks DP, Ohlstein EH, Contino LC, Storer B, Pullen M, Caltabiano M, et al: Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. Eur J Pharmacol 1991; 194:115-117.
9. Perico N, Dadan J, Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990; 1:76-83.
10. Fogo A, Hellings SE, Inagami T, Kon V: Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 1992; 42:770-774.
11. Bloom IT, Bentley FR, Garrison RN: Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 1993; 114:480-487.
12. Boulanger C, Lus̈cher T: Release of endothelin from the porcine aorta. J Clin Invest 1990; 85:587-590.
13. Hirata Y, Matsuoka H, Kimura K, Sugimoto T, Hayakawa H, Suzuki E, et al: Role of endothelium-derived relaxing factor in endothelin-induced renal vasoconstriction. J Cardiovasc Pharmacol 1991; 17(suppl 7):S169-S171.
14. Lang D, Lewis M: Endothelium-derived relaxing factor inhibits the endothelin-1-induced increase in protein kinase C activity in rat aorta. J Pharmacol 1991; 104:139-144.
15. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, et al: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91:1367-1373.
16. Kohan D, Padilla E: Endothelin-1 production by rat inner medullary collecting duct: effect of nitric oxide, cGMP, and immune cytokines. Am J Physiol 1994; 266:F291-F297.
17. Tsukahara H, Ende H, Magazine H, Bahou W, Goligorsky M: Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: receptor coupling to nitric oxide synthase. J Biol Chem 1994; 269:21778-21785.
18. Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, et al: Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 1995; 91:1229-1235.
19. Rubinstein I, Gurbanov K, Huffman A, Better O, Winaver J: Differential effect of endothelin-1 on renal regional blood flow: role of nitric oxide. J Cardiovasc Pharmacol 1995; 26(suppl 3): S208-S210.
20. Chou S-Y, Porush J: Renal actions of endothelin-1 and endothelin-3: interactions with the prostaglandin system and nitric oxide. Am J Kidney Dis 1995; 26:116-123.
21. Diederich D, Skopec J, Diederich A, Dai F-X: Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994; 23:957-961.
22. 2-cyclosporine. Transplant Proc 1985; 17:1362-1364.
23. Todo S, Porter KA, Kam I, Lynch S, Venkataramanan R, DeWolf A, et al: Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation 1986; 41:296-300.
24. White DJG, Caine RY, Collier SJ, Rolles K, Winter S, Drakopoulos S: Is cyclosporine G more or less immunosuppressive than cyclosporine A? Tranplant Proc 1986; 18:1244-1245.
25. Hagberg RC, Hoyt EG, Billingham ME, Sibley RK, Starnes VA, Baldwin JC: Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity, and pharmacokinetics in Lewis rats. J Heart Transplant 1988; 7:359-369.
26. Grant D, Freeman D, Keown P, Stiller C, Toman A, Blacker K: Pharmacokinetic and pharmacodynamic profiles of cyclosporine and cyclosporine G in dogs. Transplant Proc 1987; 19:3494-3495.
27. 2)-cyclosporine - less potent than cyclosporine A in rats with lung and heart transplants. Transplantation 1987; 44:5-8.
28. 2-cyclosporine in primate cardiac transplantation. Transplantation 1987; 43:13-17.
29. Hoyt EG, Hagberg RC, Billingham ME, Baldwin JC, Jamieson SW: Analysis of the immunosuppressive and nephrotoxic effects of cyclosporin G. J Heart Transplant 1988; 7:111-117.
30. Rayat G, Yatscoff R, Silverman R, McKenna R: A comparison of the immunosuppressive effects of cyclosporine A and cyclosporine G in vivo and in vitro. Transplantation 1993; 55:623-626.
31. Masri MA, Naiem M, Pingle S, Daar AS: Cyclosporine A versus cyclosporine G: a comparative study of survival, hepatotoxicity, nephrotoxicity, and splenic atrophy in BALB/c mice. Transpl Int 1988; 1:13-18.
32. Faraci M, Vigeant C, Yale JF: Pharmacokinetic profile of cyclosporine A and G and their effects on cellular immunity and glucose tolerance in male and female Wistar rats. Transplantation 1988; 45:617-621.
33. 2)-cyclosporine, and isradipine, a new calcium antagonist. Transplantation 1988; 46:566-569.
34. Tejani A, Lancman I, Pomrantz A, Khawar M, Chen C: Nephrotoxicity of cyclosporine A and cyclosporine G in a rat model. Transplantation 1988; 45:184-187.
35. Burdmann EA, Rosen S, Lindsley J, Elzinga L, Andoh T, Bennett WM: Production of less chronic nephrotoxicity by cyclosporine G than cyclosporine A in a low-salt rat model. Transplantation 1993; 55:963-966.
36. Burdmann E, Andoh T, Rosen S, Lindsley J, Munar M, Elzinga L, et al: Experimental nephrotoxicity, hepatotoxicity, and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int 1994; 45:684-691.
37. Kovarik J, Mueller E, Kallay Z, Smith H, Lison A, Arns W, et al: Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation. J Clin Pharmacol 1995; 35:1136-1143.
38. Henry M, Elkhammas E, Davies E, Ferguson R: A clinical trial of cyclosporine G in cadaveric renal transplantation. Pediatr Nephrol 1995; 9(suppl):S49-S51.
39. Burdmann E, Andoh T, Lindsley J, Russell J, Bennett W, Porter G: Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Renal Failure 1994; 16:161-168.
40. Wiland P, Szechinski J: N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Arch Immunol Ther Exp 1994; 42:331-336.
41. 15N] nitrate in biological fluids. Anal Biochem 1982; 126:131-138.
42. Yakata M, Sugita O, Sakai T, Uchiyama K, Wada K: Urinary enzyme determination and its clinical significance: C. Enzyme derived from the kidney tubular epithelium-N-acetyl-b-D-glucosaminidase: 4. preclinical evaluation of the urinary NAG activity and changes in renal diseases. Jap J Clin Pathol 1983; 56(suppl):90-101.
43. Roci ML, Jusko WJ: LAGRAN program. Area and moments in pharmacokinetic analysis. Comput Prog Biomed 1983; 16:203-216.
44. D'Argenio DZ, Schumitzky A: ADAPT II. A program package for simulation, identification, and optimal experimental design: user's manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA, 1992.
45. Wenk M, Bindschedler M, Costa E, Zuber M, Vozeh S, Thiel G, et al: Pharmacokinetics of cyclosporine G in patients with renal failure. Transplantation 1988; 45:558-561.
46. Huser B, Thiel G, Oberholzer M, Beveridge T, Bianchi L, Mihatsch MJ, et al: The efficacy and tolerability of cyclosporine G in human kidney transplant recipients. Transplantation 1992; 54:65-69.
47. Henry ML, Elkhammas EA, Tesi RJ, Ferguson RM: A randomized prospective trial of OG 37-325 versus cyclosporine in cadaveric renal transplantation. Abstr Ann Mtg Am Soc Transplant Physicians 1993; 12:125.
48. Ohlman S, Lindholm A, Gabel H, Wilczek H, Tyden G, Reinholt F, et al: A randomized pilot study of cyclosporin G in renal transplantation. Transplant Int 1992; 5(suppl 1):S464-S469.
49. Duncan JI, Thomson AW, Simpson JG, Davidson RJ, Whiting PH: A comparative toxicological study of cyclosporine and Nva2-cyclosporine in Sprague-Dawley rats. Transplantation 1986; 42:395-399.
50. Calne RY, White DJ, Thiru S, Rolles K, Drakopoulos S, Jamieson NV: Cyclosporin G: immunosuppressive effect in dogs with renal allografts (letter). Lancet 1985; 1:1342.
51. Grant D, Zhong R, Stiller C, Wallace C, Keown P, Duff J: A comparison of cyclosporine A and Nva2-cyclosporine (cyclosporine G) in a rat renal allograft model. Transplantation 1987; 44:9-12.
52. 2-cyclosprine in dogs. Transplant Proc 1987; 19:1265-1266.
53. D'Souza MJ, Gourdikian KB, Mujukian AL: Comparison of cyclosporine A and G pharmacokinetics. Drug Metab Dispos Biol Fate Chem 1988; 16:895-897.
54. Yatscoff R, Honcharik N, Lukowski M, Thliveri J, Chackowsky P, Faraci C: Distribution of cyclosporin G (Nva2 cyclosporin) in blood and plasma. Clin Chem 1993; 39:213-217.
55. Mangold J, Schran H, Tse F: Pharmacokinetics and metabolism of cyclosporin G in humans. Drug Metab Dispos 1994; 22:873-879.
56. Yatscoff R, Copeland K, Faraci C: Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990; 36:1969-1973.
57. Kyne F, Maguire S, O'Broin S, McGing P, McCann S, Wright E: Abbott TDx "selective" assay overestimates cyclosporine in whole blood. Clin Chem 1991; 37:1657-1658.
58. Winkler M, Schumann G, Petersen D, Oellerich M, Wonigeit K: Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation. Clin Chem 1992; 38:123-126.
59. Reynolds A, Akagi H, Hjelm N: Reliability of immunoassays of cyclosporin A in blood. Clin Chem 1992; 38:1508-1510.
60. Dusci L, Hackett L, Chiswell G, Ilett K: Comparison of cyclosporine measurement in whole blood by high-performance liquid chromatography, monoclonal fluorescence polarization immunoassay, and monoclonal enzyme-multiplied immunoassay. Ther Drug Monit 1992; 14:327-332.
61. Annesley T, Coombs R, Orsulak P: Comparison of cyclosporin G (Nva2-cyclosporin) concentrations measured in whole blood by monoclonal fluorescence polarization immunoassay, monoclonal radioimmunoassay, and HPLC. Clin Chem 1993; 39:1050-1053.
62. Langman L, Leichtman A, Weitzel W, Yatscoff R: Steady-state concentration of cyclosporin G (OG37-325) and its metabolites in renal transplant recipients. Clin Chem 1994; 40:613-616.
63. Yatscoff R, Chackowsky P: Quality assurance program for cyclosporin G (OG37-325). Ther Drug Monit 1995; 17:342-347.
64. Rosano T, Pell M, Freed B, Dybas M, Lempert N: Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc 1988; 20:330-338.
65. Yatscoff R, Rosano T, Bowers L: The clinical significance of cyclosporine metabolites. Clin Biochem 1991; 24:23-35.
66. Yatscoff R, Langman J, LeGatt D: Cross-reactivities of cyclosporin G (Nva2 cyclosporin) and metabolites in cyclosporin A immunoassays. Clin Chem 1993; 39:1089-1092.
67. Benigni A, Perico N, Gaspari F: Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991; 260:F331-F339.
68. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, et al: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39:307-311.
69. Abassi Z, Klein H, Golomb E, Keiser H: Urinary endothelin: a possible biological marker of renal damage. Am J Hypertension 1993; 6:1046-1054.
70. Langman L, Yatscoff R: Comparison of the effects of cyclosporin G (OG37-325). cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines. Ther Drug Monit 1994; 16:450-457.